These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33261142)

  • 1. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
    Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
    Liang M; Zhao T; Ma L; Guo Y
    Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    Bryant C; Rawlinson R; Massey AJ
    BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
    Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
    PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
    Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
    Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
    Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
    Hastak K; Alli E; Ford JM
    Cancer Res; 2010 Oct; 70(20):7970-80. PubMed ID: 20798217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
    Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J
    Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.
    Hsu WH; Zhao X; Zhu J; Kim IK; Rao G; McCutcheon J; Hsu ST; Teicher B; Kallakury B; Dowlati A; Zhang YW; Giaccone G
    J Thorac Oncol; 2019 Jun; 14(6):1032-1045. PubMed ID: 30771522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells.
    Krkoška M; Paruch K; Šošolíková T; Vázquez-Gómez G; Herůdková J; Novotný J; Ovesná P; Sova P; Hyršlová Vaculová A
    Biol Chem; 2024 Jun; 405(6):395-406. PubMed ID: 38452398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
    Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.